|Security||ATRS / Antares Pharma, Inc. (036642106)|
|Industry||Surgical and Medical Instruments and Apparatus|
|Common Stock Shares Outstanding||157,437,000 shares (as of 2018-06-30)|
Stock Insider Trading (from SEC Form 4)
Antares Pharma, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
ATRS / Antares Pharma, Inc. insiders include HOBBS EAMONN P, Tursi James Patrick, Stacey Jennifer Evans, DEERFIELD PARTNERS, L.P., and APPLE ROBERT F, GRAHAM PETER J, ROCHE ROBERT P JR, Deerfield International Master Fund, L.P. Deerfield Mgmt L.P., Powell Fred M, GARRITY THOMAS J, GONELLA JACQUES, SAMSON MARVIN, Fickenscher James E, JACOB LEONARD S, Flynn James E, Deerfield Special Situations Fund, L.P., GUETH ANTON, DEERFIELD MANAGEMENT CO, .
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||Powell Fred M||A||D||2.70||91,667||413,492|
|4||Powell Fred M||F||D||2.70||-9,609||321,825|
|4||GRAHAM PETER J||A||D||2.70||91,667||289,173|
|4||GRAHAM PETER J||F||D||2.70||-12,923||197,506|
|4||APPLE ROBERT F||A||D||2.70||305,556||1,530,562|
|4||APPLE ROBERT F||F||D||2.70||-32,031||1,225,006|
|4||GRAHAM PETER J||F||D||2.69||-15,422||210,429|
|4||APPLE ROBERT F||F||D||2.69||-34,402||1,257,037|
|4||APPLE ROBERT F||F||D||2.43||-13,480||1,291,439|
|4||APPLE ROBERT F||F||D||2.52||-30,052||1,304,919|
|4||APPLE ROBERT F||M||D||0.85||82,500||1,334,971|
|4||JACOB LEONARD S||M||D||0.85||32,407||239,892|
|4||APPLE ROBERT F||F||D||2.20||-37,001||1,252,471|
|4||APPLE ROBERT F||A||D||113,835||1,289,472|
|4||JACOB LEONARD S||S||X||D||4.0521||-200,000||207,485||840,750|
|4||JACOB LEONARD S||M||X||D||0.50||188,600||407,485|
|4||JACOB LEONARD S||S||X||D||4.05||-30,000||218,885||886,484|
|4||JACOB LEONARD S||M||X||D||0.85||30,000||248,885|
|4||GARRITY THOMAS J||S||X||D||3.50||-30,000||160,213||560,746|
|4||GARRITY THOMAS J||M||X||D||0.85||30,000||190,213|
|4||Powell Fred M||P||D||2.7944||130,000||331,434||926,159|
|4||GRAHAM PETER J||A||D||2.66||101,434||225,851|
|4||GRAHAM PETER J||F||D||2.57||-16,633||124,417|
|4||Powell Fred M||A||D||2.66||101,434||201,434|
|4||APPLE ROBERT F||A||D||2.66||-338,115||1,175,637|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
2017-10-31 - Asif
Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...
12h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
13h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
13h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
Management strategy of pursuing a combination of proprietary and partnered drugs is derisking future growth while providing enhanced upside with proprietary offerings. (23-0)
Discussion: Bristol-Myers Squibb's (BMY) OPDIVO (nivolumab) is now FDA approved for patients with metastatic small cell lung cancer (‘SCLC) that has progressed after platinum-based chemo and at least one prior line of therapy. This is the first and till date only FDA-approved Immuno-Oncology treatment option for this patient category. Also because this is the first successful checkpoint inhibitor to be approved for these indications, the researchers consider approval of nivolumab to be “particularly exciting. (20-1)
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q2 earnings call.
Antares Pharma, Inc. (NASDAQ:ATRS) Q2 2018 Results Earnings Conference Call August 7, 2018 8:30 AM ET (2-0)
A study from 2009 by Alok Kumar found retail investors exhibit “a greater propensity to gamble” as compared to institutional investors. (62-1)
as of ET